The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Dupilumab: A review of its use in the treatment of atopic dermatitis
Abstract
Atopic dermatitis (AD) is a chronic, pruritic immune-mediated inflammatory dermatosis characterized by a T helper 2 (Th2) immune response phenotype and may be associated with systemic inflammation. Dupilumab is an interleukin 4 (IL-4) receptor α-antagonist that inhibits IL-4 and IL-13 signaling through blockade of the shared IL-4α subunit. Blockade of IL-4/13 is effective in reducing Th2 response. Dupilumab has recently been approved in the United States and Europe for the treatment of adult patients with moderate-to-severe AD. Clinical trials have shown that adults with moderate-to-severe AD who receive weekly or biweekly dupilumab injections have significantly improved clinical and patient-reported outcomes, including Eczema Area Severity Index, SCORing Atopic Dermatitis, Dermatology Life Quality Index, and itch Numeric Rating Scale scores. Concomitant use of topical corticosteroids along with dupilumab results in a greater improvement in signs and symptoms of AD than with use of dupilumab alone. Biomarker analyses show that dupilumab modulates the AD molecular signature and other Th2-associated biomarkers. Common adverse events reported in the clinical trials were nasopharyngitis, upper respiratory tract infection, injection site reactions, skin infections, and conjunctivitis. These were mild-to-moderate in nature, and overall rates of adverse events occurred with similar frequency between the treatment and placebo groups. There were no significant serious safety concerns identified in phase III clinical trials. Dupilumab, as monotherapy or with concomitant use of topical corticosteroids, can significantly improve clinical outcomes and quality of life in patients suffering from moderate-to-severe AD. Ongoing studies of dupilumab will help determine the clinical efficacy and safety profile of its long-term use.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This dampens the T H 2 inflammatory response, thereby improving the symptoms associated with atopic dermatitis.1,2”
From Dupilumab for Allergic Contact Dermatitis: An Overview of Its Use and Impact on Patch Testing. (2022) · cites this paper as [2]
In the citing paper
“Through inhibition of the IL-4Rα subunit, it prevents activation of the IL-4/IL-13 signaling cascade.”
From Dupilumab for Allergic Contact Dermatitis: An Overview of Its Use and Impact on Patch Testing. (2022) · cites this paper as [2]
Citations
Cites
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610020 · Cited by 2,110
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
Beck, L. A., Thaçi, D., Hamilton, J. D., Graham, N. M. H., Bieber, T. R. M., Rocklin, R. E., Ming, J. E., Ren, H., Kao, R., Simpson, E. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314768 · Cited by 1,435
Blauvelt, A., de Bruin-Weller, M. S., Gooderham, M., Cather, J. C., Weisman, J. D., Pariser, D. M., Simpson, E. L., Papp, K. A., Hong, H.-K., Rubel, D. M., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31191-1 · Cited by 1,282
Self-citationEczema Prevalence in the United States: Data from the 2003 National Survey of Children's Health
Shaw, T., Currie, G. P., Koudelka, C. W., & Simpson, E. L. (2010) · Journal of Investigative Dermatology · doi:10.1038/jid.2010.251 · Cited by 721
The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies
Brunner, P. M., Guttman‐Yassky, E., & Leung, D. Y. M. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.01.011 · Cited by 662
Kakinuma, T., Nakamura, K., Wakugawa, M., Mitsui, H., Tada, Y., Saeki, H., Torii, H., Asahina, A., Onai, N., Matsushima, K., et al. (2001) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2001.113237 · Cited by 574
Thaçi, D., Simpson, E. L., Beck, L. A., Bieber, T. R. M., Blauvelt, A., Papp, K. A., Soong, W., Worm, M., Szepietowski, J. C., Sofen, H. L., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00388-8 · Cited by 573
Self-citationCommonality of the IL-4/IL-13 pathway in atopic diseases
Gandhi, N. A., Pirozzi, G., & Graham, N. M. H. (2017) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2017.1298443 · Cited by 493
Deciphering the complexities of atopic dermatitis: Shifting paradigms in treatment approaches
Leung, D. Y. M., & Guttman‐Yassky, E. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.08.008 · Cited by 486
Hamilton, J. D., Suárez‐Fariñas, M., Dhingra, N., Cardinale, I. R., Li, X., Kostić, A., Ming, J. E., Radin, A. R., Krueger, J. G., Graham, N. M. H., et al. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.10.013 · Cited by 472
The Atopic March: Progression from Atopic Dermatitis to Allergic Rhinitis and Asthma
Zheng, T., Yu, J., Oh, M. H., & Zhu, Z. (2011) · Allergy Asthma and Immunology Research · doi:10.4168/aair.2011.3.2.67 · Cited by 423
The translational revolution and use of biologics in patients with inflammatory skin diseases
Noda, S., Krueger, J. G., & Guttman‐Yassky, E. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.11.015 · Cited by 202
Therapeutic Protein–Drug Interactions and Implications for Drug Development
Sm, H., Zhao, H., Lee, J., Reynolds, K. S., Zhang, L., Temple, R., & Lesko, L. J. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.308 · Cited by 142
Fleming, P., & Drucker, A. M. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.09.052 · Cited by 130
Kovalenko, P., DiCioccio, A., Davis, J. D., Li, M., Ardeleanu, M., Graham, N., & Soltys, R. A. (2016) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12136 · Cited by 68
Bullens, D. M. A., Kasran, A., Peng, X., Lorré, K., & Ceuppens, J. L. (1998) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.1998.00646.x · Cited by 44
Diagnosis and Management of Conjunctivitis for the Dermatologist
Gooderham, M., McDonald, J., & Papp, K. A. (2017) · Journal of Cutaneous Medicine and Surgery · doi:10.1177/1203475417743233 · Cited by 31
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Interleukin‐13: Targeting an underestimated cytokine in atopic dermatitis
Bieber, T. (2020) · Allergy · doi:10.1111/all.13954 · Cited by 382
JAK–STAT signaling pathway in the pathogenesis of atopic dermatitis: An updated review
Huang, I., Chung, W.-H., Wu, P., & Chen, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1068260 · Cited by 349
Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases
Virtanen, A. T., Haikarainen, T., Raivola, J., & Silvennoinen, O. (2019) · BioDrugs · doi:10.1007/s40259-019-00333-w · Cited by 284
Nakagawa, H., Nemoto, O., Igarashi, A., Saeki, H., Kaino, H., & Nagata, T. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.12.015 · Cited by 242
“Dupilumab, an inhibitor of both IL-4 and IL-13 signaling, is used in clinical settings.(39,40) Nemolizumab, an inhibitor of IL-31 signaling, has received attention for its antipruritic effect.”
BackgroundObesity alters pathology and treatment response in inflammatory disease
Bapat, S. P., Whitty, C., Mowery, C. T., Liang, Y., Yoo, A., Jiang, Z., Peters, M. C., Zhang, L., Vogel, I. A., Zhou, C., et al. (2022) · Nature · doi:10.1038/s41586-022-04536-0 · Cited by 243
Metadata
- Authors
- Gooderham, M. J., Hong, H. C.-H., Eshtiaghi, P., & Papp, K. A.
- Affiliations
- Queen's University (CA)
- University of British Columbia (CA)
- Probity Medical Research (CA)
- Corresponding author
- Gooderham, Melinda J.
- Venue
- Journal of the American Academy of Dermatology
- Publisher
- Elsevier BV
- Published
- 2018-03
- Volume
- 78
- Issue
- 3
- Pages
- S28-S36
- ISSN
- 0190-9622 (ISSN-L)
- OpenAlex
- W2789024274
- Cited by
- 343
- References
- 17
- Citations by year
- 2026: 30 · 2025: 39 · 2024: 40 · 2023: 41 · 2022: 47 · 2021: 64 · 2020: 43 · 2019: 28 · 2018: 10
- FWCI
- 39.26
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of the American Academy of Dermatology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Bayer
- LEO Pharma
- Sanofi
- Topics
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Keywords
- dupilumab, atopic dermatitis, IL-4 receptor alpha antagonist, IL-4/IL-13 signaling, Th2 immune response, topical corticosteroids, biomarkers, adverse events, quality of life, moderate-to-severe atopic dermatitis
- MeSH terms
- Patient Reported Outcome Measures, Antibodies, Monoclonal, Biological Products, Dermatitis, Atopic, Female, Humans, Male, Quality of Life, Severity of Illness Index, Drug Delivery Systems, Treatment Outcome, Clinical Trials, Phase III as Topic, Risk Assessment, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
